Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00796952
Other study ID # BM009
Secondary ID
Status Completed
Phase Phase 2
First received November 21, 2008
Last updated September 16, 2011
Start date November 2001
Est. completion date April 2005

Study information

Verified date September 2011
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Swallowing dysfunction after chemo-radiation is common, but there is no reliable evidence for how it should be managed. This pilot randomized controlled trial evaluated the relative benefit of a battery of isometric / isotonic exercises on the maintenance of muscle composition and function for swallowing in Head / Neck Cancer patients undergoing chemo-radiation therapy.


Description:

Swallowing deficits resulting from oropharyngeal cancer and the ablative therapies used to control the disease are often devastating to the functional feeding outcome in these patients. Most patients will experience some degree of dysphagia along with nutritional decline. In particular, the swallowing outcome of those patients treated with external beam radiation is suggested to be poorer than those patients treated by surgical interventions alone. It has also been postulated that the formation of radiation-induced fibrotic tissue, along with the acute radiation effects (edema, mucositis, xerostomia) may act collectively to promote muscular disuse or atrophy, and the noted decline in swallowing function. We therefore suggest that a program of swallowing exercises may help facilitate and maintain muscle function in the oral cavity and pharynx during radiotherapy, thus preserving or supporting swallowing function in these patients.

This study will follow a randomized controlled trial design. Patients with confirmed head / neck cancer identified for planned radiotherapy will undergo a baseline evaluation including clinical and instrumental swallowing assessment, nutritional examination, and MRI prior to CRT. Subjects will then be randomized to one of three intervention arms representing control, placebo and intervention groups. Patients will be treated for 6 weeks and progress reassessed at 6 months. Outcome assessment will be completed by a blinded observer. Primary outcomes include; I)Oropharyngeal active muscle volume, signal intensity, and tissue composition over time as identified by T2 weighted MRI, II)Level of functional swallowing ability,III)Patient perception of swallowing function and quality of life.The results of the study will provide information on the efficacy (or lack of efficacy) of isometric / isotonic exercises for the maintenance of swallowing function post radiotherapy for Head /Neck cancer.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date April 2005
Est. primary completion date July 2004
Accepts healthy volunteers No
Gender Both
Age group 21 Years to 90 Years
Eligibility Inclusion Criteria:

- Head / neck cancer of the oropharyngeal or adjacent regions, confirmed by clinical history and exam, with positive cross sectional imaging studies and histopathological biopsy excluding other pathology.

- Planned to undergo external beam radiation therapy,

- No previous history of nonoral feeding for cancer related illness,

- Able to undergo MRI procedures.

- Physician / patient agreement to participate

Exclusion Criteria:

- Planned surgical intervention

- Existence of a co-existing neurological or medical disorder known to cause dysphagia

- Prior radiotherapy or surgery to the head / neck region that could contribute to dysphagia.

- Previous swallowing therapy within four weeks of randomization

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
focused attention sessions
Patient management by the attending Radiation oncologist "as usual". Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period.
Valchuff
Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver ("valchuff") and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment.
Pharyngocise
Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)

Locations

Country Name City State
United States University of Florida, Health Science Center Gainesville Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Florida Florida Department of Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Oropharyngeal muscle volume and signal intensity measured by T2 weighted MRI Baseline, 6 weeks( end of CRT), 6 months(following CRT) No
Primary Level of functional swallowing ability- measured by functional eating score (FOIS), clinical swallowing score, videoendoscopy and videofluoroscopic evaluation Baseline, 6 week(end of CRT), 6 months(following CRT) No
Primary Patient perception of swallowing ability Baseline, 6 weeks (end of CRT), 6 months (following CRT) No
Primary Quality of Life Baseline, 6 weeks (end of CRT), 6 months (following CRT) No
Secondary Taste perception Baseline, 6 weeks (end of CRT), 6 months (following CRT) No
Secondary Perception of smell Baseline, 6 weeks (end of CRT), 6 months (following CRT) No
Secondary Salivation rates Baseline, 6 weeks (end of CRT), 6 months (following CRT) No
See also
  Status Clinical Trial Phase
Completed NCT00670553 - A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer Phase 1
Completed NCT03799380 - DRIHNC - Dehydration Reduction in Head & Neck Cancer N/A
Completed NCT03157674 - Real-World Evidence and Treatment Patterns: Head and Neck Cancer
Completed NCT00565721 - A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Phase 2
Completed NCT00935961 - RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer Phase 1
Recruiting NCT03065062 - Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Phase 1
Completed NCT01268579 - Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma N/A
Completed NCT03712397 - Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy Phase 2
Completed NCT04040166 - Carotid PET/MRI With DOTATATE in Patients Post Head and Neck Radiation Therapy N/A
Completed NCT00736619 - Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 1
Completed NCT02375958 - PCA062 in pCAD-positive Tumors. Phase 1